THN-391

Pathos AI secured $365 million in Series D financing, reaching a post-money valuation of $1.6 billion to expand its AI-enabled platform for oncology drug development.

Therini Bio has raised $39 million in Series A extension financing, bringing total Series A funding to $75 million with support from new investors Angelini Ventures and Apollo Health Ventures.

Global pharmaceutical venture capital investments reached $6.5 billion in Q1 2025, showing a slight increase of 0.5% compared to the previous quarter despite a 9% decline in deal volume.

Therini Bio's novel monoclonal antibody THN391, targeting fibrin-driven neuroinflammation, demonstrated positive safety and tolerability results in Phase 1a trials with healthy volunteers.